Clinical and Translational
LeukoVantage: A Quest/Qiagen Partnership Providing Clinical Insights Into Myeloid Malignancies
202 views
The integration of next-generation sequencing (NGS) into the diagnostic process for hematologic malignancies has greatly improved the accuracy and speed of confirming or refining the diagnosis and following minimal residual disease. Optimization of gene selection and assay development, together with skilled interpretation, are key factors in the execution of a clinically relevant NGS test for hematologic malignancies.
In this webinar, we will describe Quest’s LeukoVantage assay, an NGS test designed specifically for detecting clinically relevant variants in myeloid malignancies, and its partnership with N-of-One, a QIAGEN company, for expert interpretation. LeukoVantage covers the most important genes for myeloid diagnostics, with focused panels that allow rapid turnaround. N-of-One’s team of experienced PhDs provides expert, evidence-based annotation incorporating WHO, NCCN, and ELN guidelines, with clinically relevant information vetted by oncologists. N-of-One reports include diagnostic and prognostic information, therapeutic options, and clinical trials based on the unique combination of genomic alterations detected in each case. These reports are then reviewed, modified, and signed out by Quest pathologists.
Interested in learning more?
Click here
Related videos
Clinical and Translational
How to reduce your test turnaround for large panels in molecular oncology
Speaker: Sheryl Elkin, CSO, N-of-One.a QIAGEN Company Interested in learning...
Clinical and Translational
Cancer Gene Variant Detection Using a Pre-Optimized Sample to Report Workflow
BRCA1/BRCA2 genes represent the best examples for our current understanding...
Clinical and Translational
Increasing the efficiency of diagnostic odysseys
Despite rapid cost reductions in sequencing technologies and an...
Clinical and Translational
Managing Multiple Biomarker Therapeutic Development
For the past two decades, the paradigm in the field has been “one biomarker,...